1. Home
  2. BTDR vs COGT Comparison

BTDR vs COGT Comparison

Compare BTDR & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

BTDR

Bitdeer Technologies Group

HOLD

Current Price

$10.97

Market Cap

5.5B

Sector

Technology

ML Signal

HOLD

Logo Cogent Biosciences Inc.

COGT

Cogent Biosciences Inc.

HOLD

Current Price

$39.51

Market Cap

6.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BTDR
COGT
Founded
2021
2014
Country
Singapore
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
6.5B
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
BTDR
COGT
Price
$10.97
$39.51
Analyst Decision
Strong Buy
Buy
Analyst Count
10
13
Target Price
$28.30
$30.00
AVG Volume (30 Days)
6.7M
2.9M
Earning Date
11-10-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$464,436,000.00
N/A
Revenue This Year
$73.71
N/A
Revenue Next Year
$92.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
17.40
N/A
52 Week Low
$6.84
$3.72
52 Week High
$27.80
$43.73

Technical Indicators

Market Signals
Indicator
BTDR
COGT
Relative Strength Index (RSI) 40.56 61.77
Support Level $9.66 $37.23
Resistance Level $10.49 $42.25
Average True Range (ATR) 0.80 2.23
MACD 0.13 -0.87
Stochastic Oscillator 34.70 35.13

Price Performance

Historical Comparison
BTDR
COGT

About BTDR Bitdeer Technologies Group

Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.

About COGT Cogent Biosciences Inc.

Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.

Share on Social Networks: